Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease

Khadijah Zai, Masato Hirota, Takahiro Yamada, Narumi Ishihara, Takeshi Mori, Akihiro Kishimura, Koichiro Suzuki, Kouji Hase, Yoshiki Katayama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

Original languageEnglish
Pages (from-to)94-102
Number of pages9
JournalJournal of Controlled Release
Volume286
DOIs
Publication statusPublished - 2018 Sep 28

Fingerprint

Cholecalciferol
Therapeutic Uses
Inflammatory Bowel Diseases
Lipids
Dextran Sulfate
Colitis
Oral Administration
Colon
Neutrophils
Anti-Inflammatory Agents
Therapeutics
Macrophages
Clinical Trials
Cytokines

Keywords

  • Inflammatory bowel disease
  • Inflammatory disease
  • Nanostructured lipid carrier
  • Oral administration
  • Vitamin D

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease. / Zai, Khadijah; Hirota, Masato; Yamada, Takahiro; Ishihara, Narumi; Mori, Takeshi; Kishimura, Akihiro; Suzuki, Koichiro; Hase, Kouji; Katayama, Yoshiki.

In: Journal of Controlled Release, Vol. 286, 28.09.2018, p. 94-102.

Research output: Contribution to journalArticle

Zai, K, Hirota, M, Yamada, T, Ishihara, N, Mori, T, Kishimura, A, Suzuki, K, Hase, K & Katayama, Y 2018, 'Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease', Journal of Controlled Release, vol. 286, pp. 94-102. https://doi.org/10.1016/j.jconrel.2018.07.019
Zai, Khadijah ; Hirota, Masato ; Yamada, Takahiro ; Ishihara, Narumi ; Mori, Takeshi ; Kishimura, Akihiro ; Suzuki, Koichiro ; Hase, Kouji ; Katayama, Yoshiki. / Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease. In: Journal of Controlled Release. 2018 ; Vol. 286. pp. 94-102.
@article{14f47eb0c2254de383dd53879a4d64d8,
title = "Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease",
abstract = "The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.",
keywords = "Inflammatory bowel disease, Inflammatory disease, Nanostructured lipid carrier, Oral administration, Vitamin D",
author = "Khadijah Zai and Masato Hirota and Takahiro Yamada and Narumi Ishihara and Takeshi Mori and Akihiro Kishimura and Koichiro Suzuki and Kouji Hase and Yoshiki Katayama",
year = "2018",
month = "9",
day = "28",
doi = "10.1016/j.jconrel.2018.07.019",
language = "English",
volume = "286",
pages = "94--102",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease

AU - Zai, Khadijah

AU - Hirota, Masato

AU - Yamada, Takahiro

AU - Ishihara, Narumi

AU - Mori, Takeshi

AU - Kishimura, Akihiro

AU - Suzuki, Koichiro

AU - Hase, Kouji

AU - Katayama, Yoshiki

PY - 2018/9/28

Y1 - 2018/9/28

N2 - The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

AB - The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

KW - Inflammatory bowel disease

KW - Inflammatory disease

KW - Nanostructured lipid carrier

KW - Oral administration

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=85050176611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050176611&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.07.019

DO - 10.1016/j.jconrel.2018.07.019

M3 - Article

VL - 286

SP - 94

EP - 102

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -